Drug intelligence / Profile preview

TVAX-006

Development stage: Unknown
Lead developer: Grandway SaviXin Life Sciences
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

TVAX-006 is a recombinant protein subunit vaccine candidate developed by Grandway SaviXin Life Sciences (Nanjing) for the prevention of herpes zoster (shingles). Produced using a Chinese Hamster Ovary (CHO) cell expression system, the vaccine is designed to elicit protective immune responses against the Varicella-Zoster Virus (VZV). It is currently in Phase 1 clinical development in China, where it is being evaluated for safety, tolerability, and immunogenicity in healthy adults aged 40 years and older.

Other names: recombinant herpes zoster vaccine (CHO cells)

Targets

TLR9 (Toll-like receptor 9)gE (VZV glycoprotein E)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on TVAX-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TVAX-006.

Explore the full profile